⚠️ ALL PRODUCTS ARE FOR RESEARCH PURPOSES ONLY ⚠️
⚠️ ALL PRODUCTS ARE FOR RESEARCH PURPOSES ONLY ⚠️
$99.99 / month – $849.99
Research-grade PT-141 nasal spray delivering 10mg of bremelanotide — a synthetic melanocortin receptor agonist peptide — via convenient intranasal administration. Independently verified at 99%+ purity via HPLC and mass spectrometry by an ISO-accredited laboratory.
For research use only. Not for human consumption.
Looking to buy PT-141 nasal spray for advanced melanocortin receptor research? PrymaLab offers research-grade PT-141 peptide nasal spray (bremelanotide) with verified 99%+ purity via independent HPLC test. Our intranasal form delivers 10mg of bremelanotide in a ready-to-use, pre-calibrated metered spray — removing the need for mixing, syringes, or under-skin injection. Each spray provides a consistent, pre-measured dose for standardized research protocols.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide consisting of seven amino acids that functions as a melanocortin receptor agonist, mainly targeting the MC4R and MC1R receptors in the central nervous system. Originally derived from the alpha-melanocyte-boosting hormone (α-MSH) analog Melanotan II, PT-141 has been the subject of extensive clinical and lab research for its role in tuning sexual function through central nervous system pathways rather than peripheral vascular mechanisms.
Unlike PDE5 inhibitors such as tadalafil or sildenafil that act on blood flow, PT-141 works through a fundamentally different pathway. Research shows it boosts dopaminergic activity in the medial preoptic area of the hypothalamus by starting melanocortin-4 receptors (MC4R) and melanocortin-3 receptors (MC3R). This mechanism was confirmed through multiple Phase II and Phase III clinical trials that led to FDA approval of bremelanotide (brand name Vyleesi) in June 2019 for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
Our PT-141 peptide nasal spray delivers 10mg of research-grade bremelanotide via intranasal use. Each spray delivers a consistent, pre-measured dose, making it greatly more practical for standardized research protocols. The current batch (PH-2026-NS087) tests at 99.4% purity via independent HPLC test, with full mass spectrometry confirmation of correct cell-level identity.
Research Summary: PT-141 (CAS: 189691-06-3) is a cyclic 7-amino-acid peptide with a half-life of 2.7 hours and 100% under-skin uptake. It acts as an agonist at MC4R, MC1R, MC3R, MC5R, and MC2R melanocortin receptors. Over 10 published clinical trials and multiple FDA reviews have documented its pharmacological profile.
Complete technical data for PT-141 (bremelanotide) 10mg nasal spray:
| Specification | Detail |
|---|---|
| Product Name | PT-141 Nasal Spray (Bremelanotide) |
| Quantity | 10mg total (about 30 metered sprays) |
| Form | Intranasal spray solution |
| Purity | ≥99% (HPLC verified — current batch: 99.4%) |
| CAS Number | 189691-06-3 |
| Cell-level Formula | C50H68N14O10 |
| Cell-level Weight | 1025.18 g/mol |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Mechanism | Melanocortin receptor agonist (MC4R, MC1R, MC3R, MC5R, MC2R) |
| Half-Life | 2.7 hours (range: 1.9–4.0 hours) |
| Testing | Independent third-party HPLC + mass spectrometry |
| Certificate of Test | Batch-specific COA included with every order |
| Storage | 2–8°C (refrigerator). Keep away from direct light. Stable for 12 months. |
| SKU | PT141-NS-10MG-001 |
The research interest in PT-141 spans multiple domains, driven by its unique mechanism of action that targets central nervous system melanocortin receptors rather than peripheral vascular pathways. This central mechanism makes it a valuable tool for researchers studying the neurobiology of sexual function, melanocortin signaling, and dopaminergic pathways.
Every batch of our PT-141 nasal spray is tested by an independent, ISO 17025-accredited laboratory — not just by in-house quality control. You get a batch-specific Certificate of Test (COA) showing exact purity percentages, impurity profiles, and cell-level identity confirmation via mass spectrometry. Our current batch tests at 99.4% purity via HPLC, with full MS confirmation of the correct 1025.18 g/mol cell-level weight.
Unlike freeze-dried PT-141 powder that needs mixing with sterile water, our nasal spray format is ready to use out of the box. Each actuation delivers a consistent, calibrated dose — removing variability from manual mixing and syringe measurement. The spray mechanism was tested for 50+ actuations to ensure consistent volume supply (coefficient of variation <5%).
Researchers often compare the nasal spray and under-skin injection supply methods for PT-141 (bremelanotide). Both approaches have distinct benefits depending on your research design, and grasp these differences helps optimize your experimental protocols.
| Feature | PT-141 Nasal Spray | PT-141 SC Injection |
|---|---|---|
| Use | Intranasal — non-invasive, no needles | Under-skin injection via syringe |
| Preparation | Ready to use — no mixing | Needs mixing with sterile water |
| Dosing Precision | Pre-calibrated metered spray (<5% CV) | Manual syringe measurement (user-dependent) |
| Uptake | Intranasal absorption (varies by form) | 100% (published FDA data) |
| Onset (Tmax) | Rapid nasal mucosal absorption | ~1 hour (published PK data) |
| Storage After Opening | 12 months at 2–8°C | 30 days at 2–8°C after mixing |
| Contamination Risk | Sealed spray mechanism — minimal | Needs sterile technique for each use |
| Best For | Standardized protocols, convenience | PK studies, max uptake research |
The nasal spray supply route has gained major research attention because intranasal peptide supply can bypass first-pass body function and offers direct access to the central nervous system via the olfactory and trigeminal nerve pathways. For researchers prioritizing convenience, dosing consistency, and reduced contamination risk, the PT-141 nasal spray offers clear practical benefits. For studies needing confirmed 100% uptake, under-skin injection remains the gold-standard route documented in published pharmacokinetic literature.
Proper use technique ensures consistent dosing across research protocols. Follow these steps for best results with the PT-141 peptide nasal spray:
Allow the nasal spray bottle to reach room heat (about 10–15 minutes). Do not heat or microwave. Verify the seal is intact before first use.
Remove the cap and hold the bottle upright. Press the actuator 3–4 times until a fine mist appears. This primes the pump and ensures the first research dose is accurately metered. Re-priming is needed if unused for more than 7 days.
Insert the spray tip into the nostril. Press the actuator firmly once for a single metered dose. Each actuation delivers about 333mcg of PT-141 (bremelanotide). For alternate-nostril protocols, give the next spray in the opposite nostril.
Document the number of sprays, nostril used, and exact time of use in your research log. Consistent record-keeping is essential for reproducible results.
Replace the cap and return the bottle to 2–8°C storage immediately after use. Avoid leaving at room heat for extended periods. The spray remains stable for 12 months when stored properly.
Important Research Note: Published clinical trial data for bremelanotide used under-skin injection at 1.75mg per dose. PT-141 dosage protocols for intranasal research should be found based on your specific study design and institutional rules. This product is sold for research purposes only.
Grasp PT-141 dosage parameters is essential for designing effective research protocols. The following data is compiled from published clinical trial results and FDA-reviewed pharmacokinetic studies.
| Parameter | Published Data | Source |
|---|---|---|
| FDA-Approved Clinical Dose | 1.75mg under-skin injection | FDA Label (Vyleesi, 2019) |
| Tmax (Time to Peak) | 1.0 hour (range: 0.5–1.0 hours) | FDA Pharmacokinetic Data |
| Half-Life | 2.7 hours (range: 1.9–4.0 hours) | DrugBank / FDA Label |
| Uptake (SC) | 100% | FDA Label |
| Volume of Distribution | 25.0 ± 5.8 L | FDA Pharmacokinetic Data |
| Protein Binding | 21% | FDA Label |
| Clearance | 6.5 ± 1.0 L/hr | FDA Pharmacokinetic Data |
| Sprays per Bottle | ~30 metered actuations | Product Specification |
| Dose per Spray | ~333mcg bremelanotide | Product Specification |
Dosage Note for Researchers: All dosage data presented here is derived from published, peer-reviewed clinical trial data and FDA-approved labeling. Specific PT-141 dosage for your research protocols should be found by your principal investigator based on your study objectives, model system, and institutional approval.
Store the PT-141 nasal spray at 2–8°C (standard refrigerator heat) for maximum shelf life. The sealed spray mechanism protects the peptide solution from contamination and oxidation, providing a 12-month shelf life when stored properly. Keep the bottle away from direct light and do not freeze. Unlike freeze-dried PT-141 powder that needs -20°C storage and careful mixing, the nasal spray format is ready to use directly from the refrigerator — simply allow 10–15 minutes to reach room heat before use.
PT-141 (bremelanotide) has a plasma half-life of about 2.7 hours (range 1.9–4.0 hours) based on published pharmacokinetic data from the FDA-approved label. Peak plasma level (Tmax) is reached within 1 hour of use. Research protocols often see effects within a 6–8 hour window following dosing, though the compound is largely cleared from plasma within 12 hours.
In clinical research trials reviewed by the FDA, the most often reported side effects of PT-141 (bremelanotide) include nausea (reported in about 40% of clinical trial participants), headache, facial flushing, and injection-site reactions. The nasal spray supply format may also cause temporary nasal congestion or mild nasal irritation. Transient, non-clinically-major increases in blood pressure have also been documented. MC1R agonism may cause focal hyperpigmentation with repeated use.
Both supply methods offer distinct benefits depending on research objectives. The nasal spray provides faster use, removes the need for mixing with sterile water, and delivers consistent pre-measured dosing with less contamination risk. Under-skin injection achieves documented 100% uptake per FDA pharmacokinetic data. For standardized, high-throughput protocols where convenience and dosing consistency are priorities, nasal spray is often preferred. For pharmacokinetic studies needing confirmed uptake, injection remains the published reference standard.
PT-141 (bremelanotide) does not directly increase testosterone levels. Its mechanism of action operates through melanocortin receptor start in the central nervous system — mainly MC4R and MC3R receptors — which tune dopaminergic signaling in the medial preoptic area of the hypothalamus. This pathway is independent of the hypothalamic-pituitary-gonadal (HPG) axis that regulates testosterone production. PT-141 should not be confused with SARMs or testosterone-tuning compounds.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. It mainly targets MC4R and MC1R receptors in the central nervous system. Published research shows it tunes sexual function pathways by boosting dopaminergic activity in the medial preoptic area, rather than through peripheral vascular mechanisms like PDE5 inhibitors. It got FDA approval in June 2019 under the brand name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
Every peptide nasal spray we produce undergoes rigorous dual-check testing before release. Our quality assurance protocol for PT-141 includes HPLC purity test (minimum 98% needed for release — our PT-141 consistently exceeds 99%), mass spectrometry cell-level identity confirmation verifying the correct 1025.18 g/mol cell-level weight and cyclic heptapeptide structure, visual appearance and solution clarity testing, pH check for nasal compatibility, and sterility testing of the final spray form.
We publish batch-specific Certificates of Test with every order and keep a publicly accessible COA archive on our website. All analytical testing is performed by an independent, ISO 17025-accredited laboratory to ensure objectivity and accuracy — never just in-house quality control. Every COA includes the HPLC chromatogram, mass spectrum, and detailed impurity profile so you can verify our results against your own analytical standards.
For more data about our testing methodology, visit our About Us page or browse our complete Certificate of Test Archive. Researchers can also explore our full peptide catalog including BPC-157, TB-500, and other research peptides. For questions about peptides for libido research or melanocortin receptor studies, our Melanocortin Peptides Research Guide provides full background.
When you choose to buy PT-141 nasal spray from PrymaLab, you benefit from:
Add this premium PT-141 nasal spray to your cart now and experience the convenience of ready-to-use intranasal peptide supply. Join the researchers who trust PrymaLab for their peptide research needs.
This PT-141 peptide nasal spray is intended for laboratory research purposes only. Not for human consumption. Not for use in food, drugs, medical devices, or cosmetics. This product is not a drug, supplement, or food product and has not been assessed by the FDA. Buyers must be 18 years or older. Please consult all applicable federal, state, and local regulations before buying and using this product. By buying, you agree that this product will be used solely for legitimate research purposes in compliance with all applicable laws.
| Weight | N/A |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
Reviews
There are no reviews yet.